Make sure to stay updated. HAEi will keep you informed when you sign up for our newsletter.
Sign up for HAEi Newsletter and register at the same time.
Pharming Group NV is a biotech company based in Leiden, The Netherlands. Pharming has a broad product pipeline with products for several indications and in different stages of development. Lead product and under review with the European Medicines Agency (EMA) is Rhucin(R) for treatment of acute attacks of HAE. Pharming’s technologies include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products.
The Dutch biotechnology company Pharming NV is working on the approval of their recombinant C1 inhibitor product (Rhucin) in the US. Pharming’s product is derived from the milk of female rabbits that have been genetically altered to produce the human C1 inhibitor protein. Clinical trials have shown that Rhucin is a safe and effective treatment for acute HAE attacks.